A Landmark Result Announced Without Numbers
Moderna and Merck reported that their personalized mRNA cancer vaccine succeeded in a Phase 3 melanoma trial. Moderna's market value rose by nearly $45 billion in a single session, with the two companies and rival BioNTech gaining around $92 billion collectively. Neither partner released an efficacy figure.